Vivos Inc. has made a significant move by creating a new class of shares, the Series D Convertible Preferred Stock. This decision, filed with the SEC on October 5, 2026, is aimed at enhancing the company’s capital structure and providing new funding opportunities.
According to the filing, the Series D Convertible Preferred Stock will consist of 1.0 million shares out of the 10.0 million shares of authorized preferred stock. Each share will have a stated value of $1.00 and will rank senior to the company’s common stock and other equity securities that are junior to the Series D Preferred. This change is expected to provide Vivos with more flexibility in managing its financial resources.
Background
Vivos Inc., classified under the SIC code 3841 for Surgical & Medical Instruments & Apparatus, is a company listed on the OTC exchange under the ticker RDGL. The firm focuses on developing and commercializing advanced medical technologies. Recent filings indicate that Vivos is actively engaged in enhancing its capital structure and financial strategy.
What the Filing Says
The SEC filing reveals that the Series D Preferred shares will allow holders to vote on company matters, with each share granting the equivalent of fifty votes for every share of common stock issuable upon conversion. Additionally, the shares will have a liquidation preference of $1.00 per share. The filing states, “Each holder of Series D Preferred shall be entitled to vote on all matters, together with the holders of Common Stock.”
Impact
This strategic move could significantly affect various stakeholders, including current shareholders and potential investors. By issuing Series D Preferred shares, Vivos Inc. is positioning itself to attract new investment while providing existing shareholders with enhanced voting power. This could lead to a reevaluation of the company’s market position within the surgical and medical instruments industry.
What's Next
The filing does not specify what happens next, but the introduction of the Series D Preferred stock suggests that Vivos may be preparing for future capital raises or strategic initiatives aimed at growth. Investors and industry observers will be keen to see how this development influences Vivos’ operational strategies moving forward.
For further details, the full text of the Series D Certificate of Designations is available as an exhibit in the filing, providing comprehensive insights into the rights and preferences associated with these new shares.